In the tumor context, direct targeting of the A77/G198 sites of tissue protease B (CTSB) can block the lysosomal pathway of tumor cells responsible for MHC-I degradation, thus increasing the surface abundance of MHC-I to enhance the recognition and cytotoxicity of CD8+ T cells. Here, CTSB is linked to neoplasm.